- Home
- Results news
- Bliss GVS Pharma
- Q4 FY25 results
Bliss GVS Pharma Q4 FY25 results: net profit ₹16.65 crore vs ₹4.91 crore loss, revenue down 0.1%
Bliss GVS Pharma Limited reported consolidated Q4 FY25 revenue of ₹197.99 crore, down 5.9% from Q3 FY25 and broadly unchanged from Q4 FY24. The company reported a net profit of ₹16.65 crore and EPS of ₹1.47, after a net loss of ₹4.91 crore in Q4 FY24.
Key points
- Consolidated Q4 FY25 revenue was ₹197.99 crore, down 5.9% from Q3 FY25 and down 0.1% from Q4 FY24.
- EBITDA was ₹21.09 crore, down 29.2% from Q3 FY25 and 25.6% from Q4 FY24, with margin at 10.7% versus 14.2% and 14.3%, respectively.
- Net profit was ₹16.65 crore and EPS was ₹1.47, compared with a net loss of ₹4.91 crore and negative EPS of ₹0.88 in Q4 FY24.
- For FY25, revenue was ₹809.73 crore, up 5.1% from FY24, while net profit was ₹90.26 crore, up 10.6%.
- The board recommended a final dividend of 50%, or 0.50 paisa per equity share, for FY25, subject to shareholder approval.
How did Bliss GVS Pharma perform in Q4 FY25?
Bliss GVS Pharma reported consolidated Q4 FY25 revenue of ₹197.99 crore, compared with ₹210.42 crore in Q3 FY25 and ₹198.13 crore in Q4 FY24. Revenue fell 5.9% sequentially and was down 0.1% year on year, while total income was ₹210.05 crore. On the standalone basis, revenue was ₹156.0 crore and reported a net profit of ₹11.45 crore.
Consolidated EBITDA was ₹21.09 crore in Q4 FY25, down 29.2% from ₹29.79 crore in Q3 FY25 and 25.6% from ₹28.35 crore in Q4 FY24. The EBITDA margin fell to 10.7% from 14.2% in the previous quarter and 14.3% in the year-ago quarter, declines of 3.5 percentage points and 3.6 percentage points, respectively.
Profit before tax was ₹23.44 crore, compared with ₹36.42 crore in Q3 FY25 and a loss of ₹3.95 crore in Q4 FY24. Net profit was ₹16.65 crore and EPS was ₹1.47, versus ₹25.80 crore and ₹2.27 in Q3 FY25, and a net loss of ₹4.91 crore and negative EPS of ₹0.88 in Q4 FY24. The PAT margin was 8.4%, compared with 12.3% in Q3 FY25 and negative 2.5% in Q4 FY24.
| ₹ crore | Q4 FY25 | Q3 FY25 | Q4 FY24 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 197.99 | 210.42 | 198.13 | −0.1% | −5.9% |
| Other income | 12.07 | 15.27 | 5.60 | +115.5% | −21.0% |
| Total expenses | 186.61 | 189.26 | 178.48 | +4.6% | −1.4% |
| EBITDA | 21.09 | 29.79 | 28.35 | −25.6% | −29.2% |
| EBITDA margin | 10.7% | 14.2% | 14.3% | −3.6 pp | −3.5 pp |
| Profit before tax | 23.44 | 36.42 | −3.95 | turned to profit | −35.6% |
| Tax | 6.79 | 10.62 | 0.96 | +607.3% | −36.1% |
| Net profit | 16.65 | 25.80 | −4.91 | turned to profit | −35.5% |
| EPS (₹) | 1.47 | 2.27 | −0.88 | turned to profit | −35.2% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Bliss GVS Pharma's costs and profit?
Total expenses rose 4.6% year on year to ₹186.61 crore from ₹178.48 crore, despite a 12.2% fall in cost of materials to ₹76.61 crore. Employee cost rose 15.2% to ₹28.24 crore, depreciation rose 17.4% to ₹8.04 crore and total expenses also increased, while finance costs fell 9.2% to ₹1.68 crore and other expenses declined 1.1% to ₹49.23 crore.
Other income increased 115.5% to ₹12.07 crore from ₹5.60 crore in Q4 FY24, while total income rose 3.1% to ₹210.05 crore. Q4 FY24 included an exceptional charge of ₹29.20 crore, while Q4 FY25 had no exceptional item. Tax expense rose 607.3% to ₹6.79 crore from ₹0.96 crore.
Compared with Q3 FY25, total expenses were down 1.4% to ₹186.61 crore, with cost of materials down 21.4% to ₹76.61 crore and employee cost down 5.1% to ₹28.24 crore. Other expenses rose 34.3% to ₹49.23 crore and finance costs rose 55.6% to ₹1.68 crore, while other income fell 21.0% to ₹12.07 crore. No exceptional item was reported in either quarter.
| ₹ crore | Q4 FY25 | Q4 FY24 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 76.61 | 87.28 | −10.67 | −12.2% |
| Employee cost | 28.24 | 24.51 | +3.73 | +15.2% |
| Finance costs | 1.68 | 1.85 | −0.17 | −9.2% |
| Depreciation | 8.04 | 6.85 | +1.19 | +17.4% |
| Other expenses | 49.23 | 49.80 | −0.57 | −1.1% |
| Total expenses | 186.61 | 178.48 | +8.13 | +4.6% |
| Other income | 12.07 | 5.60 | +6.47 | +115.5% |
| Tax | 6.79 | 0.96 | +5.83 | +607.3% |
| Exceptional items | none | −29.20 (charge) |
Source: Company's results filing (XBRL).
How did Bliss GVS Pharma do in FY25 as a whole?
For FY25, consolidated revenue was ₹809.73 crore, up 5.1% from ₹770.24 crore in FY24, while total income rose 5.9% to ₹846.22 crore from ₹798.98 crore. The company reported no exceptional item for the full year.
Profit before tax was ₹125.64 crore, up 7.5% from ₹116.87 crore in FY24. Net profit was ₹90.26 crore, up 10.6% from ₹81.58 crore, and EPS was ₹8.02, up 10.9% from ₹7.23 in FY24.
| ₹ crore | FY25 | FY24 | Change |
|---|---|---|---|
| Revenue from operations | 809.73 | 770.24 | +5.1% |
| Profit before tax | 125.64 | 116.87 | +7.5% |
| Net profit | 90.26 | 81.58 | +10.6% |
| EPS (₹) | 8.02 | 7.23 | +10.9% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 31 March 2025, total assets were ₹1300.84 crore, compared with ₹1282.51 crore at 30 September 2024, while total equity was ₹1091.85 crore against ₹1048.04 crore. Borrowings fell to ₹70.97 crore from ₹83.29 crore and cash declined to ₹23.79 crore from ₹33.11 crore. Inventories were ₹125.73 crore, trade receivables ₹438.36 crore and trade payables ₹71.42 crore.
For FY25, operating cash flow was ₹105.91 crore, compared with ₹152.45 crore in FY24. Investing cash flow was negative ₹75.44 crore against negative ₹132.82 crore, financing cash flow was negative ₹30.34 crore against negative ₹20.89 crore, and capital expenditure was ₹76.07 crore against ₹28.33 crore. Closing cash for FY24 was ₹23.59 crore.
| ₹ crore | As of 31 March 2025 | As of 30 September 2024 |
|---|---|---|
| Total assets | 1,301 | 1,283 |
| Total equity | 1,092 | 1,048 |
| Borrowings | 70.97 | 83.29 |
| Cash and equivalents | 23.79 | 33.11 |
| Inventories | 125.73 | 131.41 |
| Trade receivables | 438.36 | 428.32 |
Source: Company's results filing (XBRL).
| ₹ crore | FY25 | FY24 |
|---|---|---|
| Cash from operations | 105.91 | 152.45 |
| Cash from investing | −75.44 | −132.82 |
| Cash from financing | −30.34 | −20.89 |
| Capital expenditure | 76.07 | 28.33 |
Source: Company's results filing (XBRL).
How has Bliss GVS Pharma done over the last 8 quarters?
Revenue over the last eight quarters peaked at ₹217.68 crore in Q2 FY25 and reached its lowest level at ₹159.52 crore in Q1 FY24. It then moved lower in each of the next two quarters, falling to ₹197.99 crore in Q4 FY25.
Net profit was highest at ₹43.04 crore in Q2 FY24 and bottomed at a loss of ₹4.91 crore in Q4 FY24. It recovered in FY25 but fell from ₹25.8 crore in Q3 FY25 to ₹16.65 crore in Q4 FY25. The EBITDA margin peaked at 25.7% in Q2 FY24 and fell to 10.7% in Q4 FY25.
What else did the company announce?
The board approved the audited standalone and consolidated FY25 results and declared an unmodified opinion on the annual audited financial results. It recommended a final dividend of 50%, or 0.50 paisa per equity share on face value of Rs.1/- each, subject to shareholder approval at the 40th AGM.
The board re-appointed BDO India LLP as internal auditor for FY25-26 and appointed AVS & Associates as secretarial auditors for five consecutive years, from FY25-26 through FY29-30, subject to shareholder approval. It also approved the transfer of the 51% holding in Greenlife Bliss Healthcare Limited, which ceased to be a step-down subsidiary.
Subject to shareholder and regulatory approvals, the board approved the issuance of up to 12,10,000 equity shares as sweat equity for non-cash consideration: 8,50,000 shares to Managing Director Gagan Harsh Sharma and 3,60,000 shares to Vice-President Vishal Vijay Rao. The nomination and remuneration committee also granted 8,62,000 stock options under the Employee Stock Options Plan 2019 at an exercise price of Rs.43 per option.
How did Bliss GVS Pharma shares react?
The filing appeared after market hours at a reference price of ₹118.0, against the previous close of ₹119.0. The stock moved down 2.1% within 5 minutes, down 2.3% within 15 minutes and down 1.9% within 30 minutes of the filing appearing.
By the reaction-day close, the stock was down 0.8% from its pre-results close, compared with a 0.9% rise for the Pharmaceuticals industry median. By the next day's close, it was up 0.2% from the pre-results close, and by the fifth session's close it was up 2.2%. The industry medians were up 2.0% and 3.5% on those closes, so Bliss GVS trailed the sector by 1.8 percentage points and 1.3 percentage points.
Earlier reaction-day moves were mixed: the stock fell 1.5% on 28 January 2025, rose 8.4% on 24 July 2024 and fell 7.2% on 2 May 2024.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | −2.1% | |
| 15 minutes | −2.3% | |
| 30 minutes | −1.9% | |
| Reaction day | −0.8% | +0.9% |
| Next day | +0.2% | +2.0% |
| 5 days | +2.2% | +3.5% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 28 January 2025 | −1.5% |
| 24 July 2024 | +8.4% |
| 2 May 2024 | −7.2% |
Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
A total of 155 Pharmaceuticals companies filed for the quarter, with a median revenue growth of 9.2%. Of these, 52 companies grew more slowly than Bliss GVS Pharma and 102 grew faster, while 87 reported higher profit across 155 profit comparisons.
| Bliss GVS Pharma revenue growth (YoY) | −0.1% |
|---|---|
| Median of 155 other Pharmaceuticals companies | +9.2% |
| Companies with slower revenue growth than Bliss GVS Pharma | 52 of 155 |
| Companies with faster revenue growth than Bliss GVS Pharma | 102 of 155 |
| Companies whose net profit rose | 87 of 155 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Bliss GVS Pharma's revenue in Q4 FY25?
Revenue from operations was ₹197.99 crore, down 0.1% from ₹198.13 crore in Q4 FY24 (consolidated).
Did Bliss GVS Pharma make a profit in Q4 FY25?
Yes. Net profit was ₹16.65 crore, against a net loss of ₹4.91 crore in Q4 FY24.
What was Bliss GVS Pharma's EPS in Q4 FY25?
Basic earnings per share were ₹1.47, against a loss of ₹0.88 in Q4 FY24.
How did Bliss GVS Pharma shares react to the Q4 FY25 results?
On the reaction day the stock moved −0.8% from the previous close; the median Pharmaceuticals stock moved +0.9%.
When did Bliss GVS Pharma announce its Q4 FY25 results?
On 12 May 2025, in a filing to the NSE.
Sources
- Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended March 31, 2025 And Recommendation Of Final Dividend If Any, For The Year Ended March 31, 2025. (BSE, 5 May 2025) · PDF
- Outcome of Board Meeting (NSE, 12 May 2025) · PDF
- Dividend (NSE, 12 May 2025) · PDF
- Outcome of Board Meeting (NSE, 12 May 2025) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.